This! Hindsight is to be avoided with more than just patents.
Amarin's litigation strategy, as unfortunate as it was, was completely in line with other investment characteristics of this 1-drug growth company. Binary, highly asymmetrical, etc.
BO suitors likely balked at a car they were merely "pretty sure" Amarin owned.